Regorafenib is a small-molecule inhibitor of multiple protein kinases and inhibited tumor angiogenesis through targeting VEGFR1, 2 and 3, PDGFR-β, FGFR1, Kit, RAS/RAF/MEK/ERK pathway and so on. This evidence concerns the gene WEE1 and neoplasm.